$340 Million is the total value of Foresite Capital Management V, LLC's 20 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | New | Cullinan Oncology, Inc. | $113,818,000 | – | 2,731,410 | +100.0% | 33.46% | – |
| GMTX | New | Gemini Therapeutics, Inc. | $32,996,000 | – | 2,435,125 | +100.0% | 9.70% | – |
| ACRS | New | Aclaris Therapeutics, Inc. | $31,708,000 | – | 1,258,243 | +100.0% | 9.32% | – |
| KNTE | Kinnate Biopharma Inc. | $27,265,000 | -21.7% | 875,001 | 0.0% | 8.02% | -68.9% | |
| ALXO | ALX Oncology Holdings Inc. | $23,597,000 | -14.5% | 320,000 | 0.0% | 6.94% | -66.0% | |
| PHVS | New | Pharvaris N.V. | $18,583,000 | – | 664,142 | +100.0% | 5.46% | – |
| NRIX | Nurix Therapeutics, Inc. | $14,038,000 | -5.4% | 451,522 | 0.0% | 4.13% | -62.5% | |
| HIMS | New | Hims & Hers Health, Inc. | $13,983,000 | – | 1,056,922 | +100.0% | 4.11% | – |
| RLAY | Relay Therapeutics, Inc. | $13,828,000 | -16.8% | 400,000 | 0.0% | 4.06% | -67.0% | |
| PHICU | Population Health Investment Co., Inc.unit | $9,648,000 | -3.8% | 960,000 | 0.0% | 2.84% | -61.8% | |
| OLK | New | Olink Holding ABsponsored ads | $7,200,000 | – | 200,000 | +100.0% | 2.12% | – |
| FSII | New | FS Development Corp. II | $6,001,000 | – | 602,500 | +100.0% | 1.76% | – |
| LHDX | New | Lucira Health, Inc. | $5,869,000 | – | 485,000 | +100.0% | 1.72% | – |
| RACB | New | Research Alliance Corp. II | $5,125,000 | – | 500,000 | +100.0% | 1.51% | – |
| BCTG | BCTG Acquisition Corp. | $4,448,000 | -2.8% | 400,000 | 0.0% | 1.31% | -61.4% | |
| LSAQ | LifeSci Acquisition II Corp. | $4,056,000 | -5.0% | 400,000 | 0.0% | 1.19% | -62.3% | |
| RACA | Therapeutics Acquisition Corp | $3,679,000 | -24.5% | 350,000 | 0.0% | 1.08% | -70.0% | |
| HLXA | Helix Acquisition Corp. | $2,550,000 | -10.3% | 250,000 | 0.0% | 0.75% | -64.4% | |
| Consonance-HFW Acquisition Corp.unit | $976,000 | -6.8% | 100,000 | 0.0% | 0.29% | -63.0% | ||
| IMVT | New | Immunovant, Inc. | $802,000 | – | 50,000 | +100.0% | 0.24% | – |
| ABCL | Exit | Abcellera Biologics Inc. | $0 | – | -20,000 | -100.0% | -0.60% | – |
| OAC | Exit | Oaktree Acquisition Corp. | $0 | – | -871,422 | -100.0% | -9.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.